EA200870498A1 - Мускариновые агонисты для лечения расстройств контроля над побуждениями - Google Patents

Мускариновые агонисты для лечения расстройств контроля над побуждениями

Info

Publication number
EA200870498A1
EA200870498A1 EA200870498A EA200870498A EA200870498A1 EA 200870498 A1 EA200870498 A1 EA 200870498A1 EA 200870498 A EA200870498 A EA 200870498A EA 200870498 A EA200870498 A EA 200870498A EA 200870498 A1 EA200870498 A1 EA 200870498A1
Authority
EA
Eurasian Patent Office
Prior art keywords
disorder
impulse control
control disorders
agonists
treatment
Prior art date
Application number
EA200870498A
Other languages
English (en)
Other versions
EA014915B1 (ru
Inventor
Натасья М.В.Й. Де Брэйн
Марлис Л. Ван Дриммелен
Арнольдус Х.Й. Херреманс
Мартинус Т.М. Тюлп
Корнелис Г. Крюсе
Original Assignee
Солвей Фармасьютикалс Б.В.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Солвей Фармасьютикалс Б.В. filed Critical Солвей Фармасьютикалс Б.В.
Publication of EA200870498A1 publication Critical patent/EA200870498A1/ru
Publication of EA014915B1 publication Critical patent/EA014915B1/ru

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/439—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom the ring forming part of a bridged ring system, e.g. quinuclidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
    • A61K31/5513—1,4-Benzodiazepines, e.g. diazepam or clozapine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia

Landscapes

  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biomedical Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Organic Chemistry (AREA)
  • Psychiatry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Hydrogenated Pyridines (AREA)

Abstract

Данное изобретение относится к новому применению соединений и их фармацевтически приемлемых солей, которые являются мускариновыми агонистами, в частности, агонистами мускариновыми 1 типа (M1). Эти соединения пригодны для приготовления фармацевтических композиций для лечения, улучшения состояния и предупреждения расстройств контроля над побуждениями. К ним относятся расстройства контроля над побуждениями "Нигде больше не классифицированные" (NEC), такие как интермиттирующее эксплозивное расстройство, пиромания, клептомания, патологическое пристрастие к азартным играм и трихотилломания; а также расстройства контроля над побуждениями "Без дополнительных уточнений" (NOS), такие как компульсивное расстройство совершения покупок, компульсивное переедание или питье, импульсивное самоповреждение, такие как патологическое ковыряние кожи, откусывание ногтей и ковыряние в носу, выдавливание глаз, битье головой и кусание самого себя; склонность к сексуальным извращениям, включая эксгибиционизм, фетишизм, фроттеризм, педофилию, мазохизм, садизм, трансвестический фетишизм и вуайеризм; компульсивное использование Интернета и чрезмерное использование мобильного телефона.
EA200870498A 2006-05-04 2007-04-23 Мускариновые агонисты для лечения расстройств контроля над побуждениями EA014915B1 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US79735506P 2006-05-04 2006-05-04
EP06113476 2006-05-04
PCT/EP2007/053934 WO2007128674A2 (en) 2006-05-04 2007-04-23 Muscarinic agonists to treat impulse control disorders

Publications (2)

Publication Number Publication Date
EA200870498A1 true EA200870498A1 (ru) 2009-04-28
EA014915B1 EA014915B1 (ru) 2011-02-28

Family

ID=38544084

Family Applications (1)

Application Number Title Priority Date Filing Date
EA200870498A EA014915B1 (ru) 2006-05-04 2007-04-23 Мускариновые агонисты для лечения расстройств контроля над побуждениями

Country Status (12)

Country Link
EP (1) EP2023909B1 (ru)
JP (1) JP2010501471A (ru)
KR (1) KR20090013815A (ru)
AT (1) ATE448778T1 (ru)
AU (1) AU2007247231B2 (ru)
CA (1) CA2649917A1 (ru)
DE (1) DE602007003348D1 (ru)
EA (1) EA014915B1 (ru)
ES (1) ES2336275T3 (ru)
IL (1) IL194778A0 (ru)
PL (1) PL2023909T3 (ru)
WO (1) WO2007128674A2 (ru)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2009140483A1 (en) 2008-05-15 2009-11-19 University Of Toledo Muscarinic agonists as cognitive enhancers
HUE044653T2 (hu) 2009-07-22 2019-11-28 PureTech Health LLC Készítmények olyan rendellenességek kezelésére, amelyek muszkarin-receptor aktiválással enyhíthetõk
US10265311B2 (en) 2009-07-22 2019-04-23 PureTech Health LLC Methods and compositions for treatment of disorders ameliorated by muscarinic receptor activation
KR101613245B1 (ko) 2015-04-27 2016-04-18 주식회사 대웅제약 신규의 4-메톡시 피롤 유도체 또는 이의 염 및 이를 포함하는 약학 조성물
NZ773719A (en) 2018-09-28 2022-07-29 Karuna Therapeutics Inc Compositions and methods for treating disorders ameliorated by muscarinic receptor activation

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IE922270A1 (en) * 1991-07-26 1993-01-27 Akzo Nv Pyrazole derivatives
US6117890A (en) * 1996-08-01 2000-09-12 Eli Lilly And Company Method for treating bipolar disorder
US20040116505A1 (en) * 2001-02-23 2004-06-17 Gregory Krauss Treatment of tics, tremors and related disorders
TW200530246A (en) * 2003-12-19 2005-09-16 Bristol Myers Squibb Co Azabicyclic heterocycles as cannabinoid receptor modulators
JP2008509147A (ja) * 2004-08-05 2008-03-27 アカディア ファーマシューティカルズ，インコーポレーテッド ヒト神経精神病を治療するためのｎ−デスメチルクロザピンの使用
GB0428170D0 (en) * 2004-12-23 2005-01-26 Biopartners Ltd Mono and Combination Therapy

Also Published As

Publication number Publication date
AU2007247231A1 (en) 2007-11-15
WO2007128674A3 (en) 2008-04-03
WO2007128674A2 (en) 2007-11-15
CA2649917A1 (en) 2007-11-15
EA014915B1 (ru) 2011-02-28
KR20090013815A (ko) 2009-02-05
ES2336275T3 (es) 2010-04-09
AU2007247231B2 (en) 2012-05-31
EP2023909A2 (en) 2009-02-18
ATE448778T1 (de) 2009-12-15
DE602007003348D1 (de) 2009-12-31
IL194778A0 (en) 2009-08-03
PL2023909T3 (pl) 2010-04-30
EP2023909B1 (en) 2009-11-18
JP2010501471A (ja) 2010-01-21

Similar Documents

Publication Publication Date Title
EA200870498A1 (ru) Мускариновые агонисты для лечения расстройств контроля над побуждениями
HK1225642A1 (zh) 用於治療假性延髓反應、神經性疾病、頑固性及慢性疼痛以及腦損傷的嗎啡喃化合物和抗抑鬱劑組合
ZA200901451B (en) Ultrasonic treatment of glaucoma
EP2397159A3 (en) Combination of morphinan compounds and antidepressant for the treatment of intractable and chronic pain
LT2878297T (lt) Medikamentai, skirti fibrozinių ligų gydymui arba prevencijai
WO2008095086A3 (en) Topiramate plus naltrexone for the treatment of addictive disorders
FR2915198B1 (fr) Derives de triazolopyridine-carboxamides et triazolopyridine -carboxamides, leur preparation et leur application en therapeutique.
WO2006099541A3 (en) Therapeutic wound care product
BRPI0712206A2 (pt) tratamento do agonista de melatonina
NZ592544A (en) Isonicotinamide orexin receptor antagonists
WO2008030367A3 (en) Selective myostatin inhibitors
WO2007003411A3 (en) Kinin antagonists for treating bladder dysfunction
FR2904316B1 (fr) Derives de n-(amino-heteroaryl)-1h-indole-2-carboxamides, leur preparation et leur application en therapeutique.
NZ580963A (en) Compositions and methods for prophylaxis and treatment of addictions
EP2192901A4 (en) CHEMICAL AGENTS, COMPOSITIONS AND METHODS FOR THE TREATMENT AND PREVENTION OF ORTHOPOXVIRUS INFECTIONS AND RELATED DISEASES
HK1084037A1 (en) Medicament for treating severe heart failure
SI2024368T1 (sl) Derivati 6,7,8,9-tetrahidro-5h-pirimido(4,5-d)azepin-4-il)-amina kot modulatorji trpv 1 za zdravljenje boleäśine
WO2006058016A3 (en) Aryl-and heteroaryl-substituted tetrahydroisoquinolines and use thereof to block reuptake of norepinephrine, dopamine and serotonin
FR2904827B1 (fr) Derives de 5,6-bisaryl-2-pyridine-carboxamide, leur preparation et leur application en therapeutique comme antiganistes des recepteurs a l'urotensine ii
IL184124A0 (en) Medicaments for the treatment or prevention of fibrotic diseases
NZ595545A (en) Compositions and methods for prophylaxis and treatment of addictions
ZA200609104B (en) Use of PPAR agonists to treat ruminants
WO2008116663A3 (en) Heterocyclyl-substituted-tetrahydro-naphthalen-amine derivatives, their preparation and use as medicaments
GB0413068D0 (en) Treatment of pulp
WO2007039123A3 (en) Combination therapy comprising an nk-3 antagonist and an antipsychotic agent

Legal Events

Date Code Title Description
MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AM KG MD TJ TM

MM4A Lapse of a eurasian patent due to non-payment of renewal fees within the time limit in the following designated state(s)

Designated state(s): AZ BY KZ RU